Accum

Defence Therapeutics is a Canadian biotechnology company focused on developing next-generation vaccines and antibody-drug conjugates (ADCs) using its proprietary Accum™ technology. The Accum™ platform is designed to enhance the intracellular delivery of biological molecules by facilitating their escape from endosomes, thereby increasing their efficacy and reducing toxicity. The company's pipeline includes programs targeting various cancers, such as breast cancer and melanoma, as well as infectious diseases. Defence Therapeutics aims to leverage its platform to improve the performance of existing therapies and develop novel therapeutic candidates. The company is publicly traded and actively pursues partnerships to advance its clinical and pre-clinical programs.